PET/MRI Scan for Cervical Cancer

Overseen By Sanaz Javadi

Age: 18+

Sex: Female

Trial Phase: Phase < 1

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: Pregnancy, Radiation history, Endometrial cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

25 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the PET/MRI Scan treatment for cervical cancer?

Research suggests that combining PET and MRI scans can improve the accuracy of evaluating how well cervical cancer treatments are working, especially after radiation therapy. PET scans are good at detecting cancer spread, while MRI provides detailed images of the body's structures, making their combination potentially more effective for assessing treatment outcomes. ^{1 2 3 4 5}

Is the PET/MRI scan safe for humans?

The pilot study on PET/MRI scans for cervical cancer did not report any safety concerns, suggesting it is generally safe for humans. However, more studies are needed to fully understand its safety profile. ^{1 6 7 8 9}

How does PET/MRI differ from other treatments for cervical cancer?

PET/MRI is a unique imaging technique that combines positron emission tomography (PET) and magnetic resonance imaging (MRI) to provide more detailed and confident diagnostic information for cervical cancer compared to the standard PET/CT. This can lead to changes in clinical management and treatment strategies, as it offers better staging and assessment of the disease. ^{5 6 10 11 12}

What is the purpose of this trial?

This trial studies how well positron emission tomography/magnetic resonance imaging (PET/MRI) scan works in checking patients with stage IA1-IB3 cervical cancer that can be removed by surgery (resectable). PET/MRI scan may help doctors learn more about the spread of the disease.

Research Team

Sanaz Javadi

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for individuals with suspected early-stage cervical cancer (IA1-IB3) that can potentially be removed by surgery. Participants must not have tumors larger than 4 cm, should have no issues with undergoing MRI scans, and will be having their surgical procedure at MD Anderson.

Inclusion Criteria

My cervical cancer is in the early stages and my tumor is not larger than 4 cm.

No contraindications to MRI

I am suspected to have cervical cancer.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic

Patients receive fludeoxyglucose F-18 and gadobutrol IV and undergo PET/MRI

90-120 minutes

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the diagnostic procedure

3 years

Treatment Details

Interventions

• PET/MRI Scan

Trial Overview The study is evaluating the effectiveness of PET/MRI scans using Gadobutrol and Fludeoxyglucose F-18 in assessing the spread of early-stage cervical cancer before surgery.

Participant Groups

Group I: Diagnostic (PET/MRI) Experimental Treatment 4 Interventions

Patients receive fludeoxyglucose F-18 and gadobutrol IV over 1 minute and undergo PET/MRI over 90-120 minutes.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

References

1. Singapore pubmed.ncbi.nlm.nih.gov

Molecular imaging in the management of cervical cancer. [2016]

2. Germany pubmed.ncbi.nlm.nih.gov

Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study. [2020]

3. United States pubmed.ncbi.nlm.nih.gov

Role of magnetic resonance imaging and positron emission tomography/computed tomography in preoperative lymph node detection of uterine cervical cancer. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer. [2018]

5. Germany pubmed.ncbi.nlm.nih.gov

Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. [2022]

6. United States pubmed.ncbi.nlm.nih.gov

18F-FDG PET/MRI Primary Staging of Cervical Cancer: A Pilot Study with PET/CT Comparison. [2021]

7. Switzerland pubmed.ncbi.nlm.nih.gov

Utilization of functional MRI in the diagnosis and management of cervical cancer. [2022]

8. Germany pubmed.ncbi.nlm.nih.gov

Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy. [2018]

9. India pubmed.ncbi.nlm.nih.gov

Role of Functional Magnetic Resonance Imaging Derived Parameters as Imaging Biomarkers and Correlation with Clinicopathological Features in Carcinoma of Uterine Cervix. [2022]

10. Germany pubmed.ncbi.nlm.nih.gov

Comparison of 18F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. [2019]

11. United States pubmed.ncbi.nlm.nih.gov

Applications of PET/MR Imaging in Urogynecologic and Genitourinary Cancers. [2017]

12. England pubmed.ncbi.nlm.nih.gov

Relative clinical utility of simultaneous 18F-fluorodeoxyglucose PET/MRI and PET/CT for preoperative cervical cancer diagnosis. [2021]